Go EuropeAIdirectory

Evidence-backed European AI register

Isomorphic Labs

Reviewed identity, roles, model listings, pricing and evidence for Isomorphic Labs.

Dataset compiled 2026-08-27 · evidence over inference

model lab2 model listings0 token-price rows

Reviewed identity

Headquarters scope
European non-EU headquarters
Headquarters record
London
Legal entity
Ltd (UK private limited company)
Ownership
subsidiary of Alphabet Inc. (US) — Alphabet remains the majority/controlling shareholder alongside external investors
Founded
2021
Confidence
high
Last verified
2026-08-22

Links

Official website

Open interactive profile

Evidence boundaries

Organisation listings identify a reviewed canonical record. Model listings show an association in the source register; they do not by themselves establish model creation, current API availability, hosting location or infrastructure ownership.

Model listings

  1. AlphaFold 3catalogued with this organisation · origin not asserted
    Type
    multimodal
    Parameters
    unknown
    Context
    unknown
    Languages
    unknown
    Licence
    research/non-commercial for the public offering; commercial use retained by Isomorphic
    Release
    2024-05
  2. Isomorphic Labs Drug Design Engine (IsoDDE)catalogued with this organisation · origin not asserted
    Type
    multimodal
    Parameters
    unknown
    Context
    unknown
    Languages
    unknown
    Licence
    proprietary
    Release
    unknown

Profile note

OWNERSHIP CAVEAT: London-headquartered and London-staffed, but an Alphabet subsidiary — CEO Demis Hassabis is simultaneously CEO of Google DeepMind. Recorded here (unlike Google DeepMind itself) because it is a separately capitalised company with its own external investors, its own $2.1B Series B in May 2026 — the largest AI-drug-discovery raise ever — and its own commercial deals with Eli Lilly and Novartis. Readers should still understand it as Alphabet-controlled, not independently European. Hassabis gave an end-of-2026 timeline for a first clinical entry at Davos in Jan 2026, a year later…

Record sources

  1. https://www.isomorphiclabs.com/our-tech
  2. https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier
  3. https://www.forbes.com/sites/amyfeldman/2026/05/13/isomorphic-labs-21-billion-fundraise-is-the-biggest-bet-ye…
  4. https://www.fiercebiotech.com/biotech/alphabets-ai-biotech-isomorphic-labs-bags-21b-series-b-fuel-next-gen-dr…
  5. https://www.isomorphiclabs.com/